INTRODUCTION 1
Multiple myeloma is a clonal malignancy of plasma cells with no known 2 cure. Like normal plasma cells, myeloma cells produce and secrete incredible 3 amounts of immunoglobulin. This unique function may be exploited by 4 therapeutically inhibiting the proteasome using the FDA-approved proteasome 5 inhibitors (PIs) bortezomib, carfilzomib, and ixazomib. Proteotoxic stress caused 6 by these first-line therapeutic agents has been proposed to induce the apoptotic 7 function of the unfolded protein response (UPR) (1), leading to plasma cell death 8 while largely sparing normal tissues (2, 3). However, despite the appealing 9 simplicity of this mechanism, the canonical UPR is not always strongly induced in 10 myeloma cells by PIs (4) and is unlikely to be the sole mode of PI cytotoxicity in 11 MM. Indeed, many additional mechanisms of action of PIs have also been 12 proposed, ranging from NF-kB inhibition to immune microenvironment effects to 13 aberrant recycling of cytosolic amino acids (5, 6). 14
Identifying the full range of PI mechanisms of action remains relevant 15
given that acquired PI resistance is clinically widespread but its origins remain 16 unclear (7, 8) and finding new methods to specifically target PI-resistant disease, 17 or molecules to synergize with PIs to avoid resistance by driving deeper 18 remissions, remains a long-standing goal. As one approach to achieving this 19 goal, we and others have studied the response of malignant plasma cells to PIs 20 using both gene expression and proteomic methods (9-11). Notably, one of the 21 most prominent features of the cellular response to PIs is the activation of the 22 heat shock response (12). This mechanism leads to significant induction of 23 cytosolic protein-folding chaperones, possibly to assist in protein refolding and 24 decrease in unfolded protein stress. We and others (9, 12, 13) have therefore 25
proposed targeting mediators of the heat shock response as potential 26 combination therapies with PIs. 27
However, one unresolved question is whether proteasome inhibition may 28 carry additional effects on plasma cells that are not revealed by mRNA or protein 29 abundance analysis alone. We hypothesized that additional modalities of 30 response, and thereby new myeloma-relevant therapeutic targets, may be 31 revealed by studying the signaling-level response to PIs with unbiased mass 1 spectrometry-based phosphoproteomics. The large majority of therapy-relevant 2 investigations using this technique have focused on elucidating the effects of 3 kinase inhibitors (14) . However, we reasoned that a significant cellular 4 perturbation such as proteasome inhibition would likely also indirectly perturb 5 kinase and phosphatase signaling in a broad fashion. 6
Here, we used unbiased phosphoproteomics to quantify >5000 7 phosphopeptides in myeloma cells exposed to the irreversible PI, carfilzomib 8 (Cfz). Surprisingly, we found the greatest increases in phosphorylation occurred 9 in proteins associated with the spliceosome machinery. A link between these 10 processes was invisible at the gene expression level. We further evaluated this 11 link from a mechanistic and therapeutic perspective, finding that PIs lead to 12 specific disruption of normal splicing. We suggest interference of splicing as an 13 additional mechanism of action of PIs not previously explored. Inhibition of 14 splicing has recently become a promising therapeutic strategy in other 15 hematologic malignancies (15). Our results reveal an intersection of cellular 16 stress and the splicing machinery, which may have broad relevance in biology. 17
Furthermore, we propose the spliceosome as a new and potentially selective 18 therapeutic target in myeloma. 19
20

RESULTS
22
Proteasome inhibition results in sustained phosphorylation of splicing 23
factors in myeloma plasma cells 24
We first used unbiased phosphoproteomics to examine the signaling-level 25 response of MM.1S multiple myeloma cells to Cfz. We chose time points across 26 24 hours for analysis based on our prior results demonstrating that the 27 transcriptional and proteomic response to proteasome inhibition evolves over 28 many hours (9). This is in contrast with the majority of prior perturbation 29 phosphoproteomic studies, which have typically examined direct effects on 30 kinase activation or inhibition on a timescale of minutes (14) . Here, we instead 31 consider the indirect effects on phosphorylation induced by PI exposure. Using 1 label-free quantification of immobilized metal affinity chromatography (IMAC)-2 isolated phosphopeptides, we indeed found that altered phosphorylation 3 signatures were most prominent 24 hours after treatment ( Fig. 1 and Fig. S1 ). In 4 total, we quantified 5791 phosphosites in at least one technical replicate of the 5 time course, with >99% of phosphosites representing Ser or Thr phosphorylation 6 events, as expected using this enrichment technique. Notably, with 30 nM Cfz, 7 cell viability was approximately 30% of baseline, indicating significant drug-8 induced cytotoxicity by this final time point. 9
At each time point we simultaneously performed single-end RNA-seq to 10 determine gene expression to compare with our phosphoproteomic results. 1B shows 58 upregulated (red) and 75 downregulated (blue) phosphopeptides 12 from proteins with largely unchanged RNA transcript abundance as detected by 13 unsupervised hierarchical clustering. Upon this initial analysis, we were 14 encouraged to find decreased phosphorylation of the translation factor EIF4E-15 BP1 as well as the ribosomal subunit RPS6 (Fig. 1B) . These phosphorylation-16 level responses related to suppressed translation are expected upon PI-induced 17 cellular stress (9). While other downregulated phosphopeptides did not suggest a 18 specific highly-enriched biological function, upon manual inspection of 19 upregulated phosphosites we were surprised to find that 14 of 58 were present 20 on proteins related to pre-mRNA splicing. These primarily included 21 phosphopeptides deriving from the heterogeneous ribonucleoprotein (HNRNP) 22 family of proteins as well as phosphopeptides belonging to the SRSF family of 23 splicing factors (Fig. 1B) . In particular, the arginine-and serine-rich "RS" domain 24 of the SRSF proteins are known to have their splicing activity modulated by 25 phosphorylation (16). Notably, these prominent signaling-level effects on splicing 26 factors were invisible to prior gene expression studies of PI response and have 27 not been investigated previously. We therefore chose to further explore the 28 interaction between PIs and the splicing machinery. 29
To validate this initial result from label free quantitative proteomics, we 30 prepared independent samples using a stable isotope labeling (SILAC) 31 phosphoproteomics approach. Based on our results above, we examined only 1 the 24 hr time point in MM.1S cells. We evaluated both a low dose (10 nM, n = 2 2 biological replicates) and a moderate dose (18 nM, n = 2) of Cfz ( Fig. 2A-B) . 3
With this lot of Cfz, 10 nM drug elicited ~20% cell death after 24 hr, while 18 nM 4 killed ~85% of cells (Fig. S3A) . Of the 520 phosphosites significantly (p < 0.05; ≥ 5 2-fold-change) upregulated in MM.1S treated with 18 nM Cfz in Fig. 2A, 127  6 (24.4%) are associated with splicing-related proteins, with 23 of these as part of 7 the SRSF protein family of splicing factors. Background-corrected Gene Ontology 8 (GO) analysis confirms that all of the top enriched biological processes involve 9 RNA splicing regulation and mRNA processing (Fig. S1B, 2E) . At 10 nM Cfz, 10 though, this signaling response is much weaker with only 25 upregulated 11 phosphosites; none of these are splicing-related. These results suggest that 12 there is a strong dose-response effect of phosphorylation changes after 13 proteasome inhibition, both across splicing factors and the broader proteome. 14 To compare these changes at the signaling level to changes at the protein 15 level, unenriched peptides were also analyzed by LC-MS/MS (Fig. S2A-B) . 16
Confirming expected responses to proteasome inhibition, the most upregulated 17 proteins included heat shock-induced chaperones as well as SQSTM1/p62 18 associated with autophagy (9). In contrast, splicing factors with increased 19 phosphorylation sites do not significantly change in abundance, confirming that 20 phosphosite increases are due to changes at the signaling level and not protein 21 copy number. 22
23
Melphalan induces a similar but not identical phosphorylation response 24
We next investigated whether this broad splicing factor phosphorylation 25 phenotype was unique to proteasome inhibition or was also seen under a 26 different drug mechanism of action. We chose to compare the response of 27 MM.1S cells to melphalan, a DNA alkylating agent and clinically-used myeloma 28 therapeutic. In parallel, we also treated another MM cell line, AMO-1, with Cfz to 29 determine if the phosphorylation response to proteasome inhibitor is consistent 30 across cell line models. 31
For these experiments we again used a single-timepoint SILAC approach. 1
Here, both 10 µM melphalan and 15 nM Cfz led to ~20% cell death in MM.1S 2 and AMO-1, respectively, at 24 hr (Fig. S3A) . Western blot confirmed induction 3 of DNA damage by melphalan and proteotoxic stress response for Cfz (Fig. S3C-4   D) . Compared to 18 nM Cfz, we saw largely decreased phosphorylation-level 5 responses to both of these agents (Fig. 2C-D) . Of 113 phosphosites significantly 6 upregulated in AMO-1, 7 belong to splicing related proteins (SRSF2, SRSF6, 7 SRRM1, HNRNPH1, TRA2A, DDX1). This result is consistent with the MM.1S 8 results in Fig. 2A-B , where greater PI response correlates with more prominent 9 phosphorylation changes. 10
Under 10 µM melphalan, 93 phosphosites were significantly upregulated, 11 with 8 sites on splicing related proteins (HNRNPK, TRA2A, SRRM2, and 12 WDR77), although none are SRSF family members (Fig. 2D) . Furthermore, as 13 expected, both unenriched shotgun proteomics and RNA-seq for gene 14 expression confirm that proteasome inhibition and DNA damage elicit different 15 responses ( Fig. S2A-E) . Again, no splicing factors with altered phosphosites 16 under either drug treatment were changed at the protein abundance level. 17
We further performed Kinase Set Enrichment Analysis (KSEA) (17) on our 18 MM.1S datasets to identify kinases whose activity may regulate differential 19 phosphorylation found by phosphoproteomics. While this tool is limited by its 20 reliance on well-characterized kinase-substrate relationships, and despite the 21 different number of phosphosites upregulated under each condition, within this 22 framework this tool identified similar kinases active under both 18 nM Cfz and 10 23 µM melphalan treatment (Fig. 2F) . Notably, both drugs are predicted to induce 24 activity of cdc2-like kinase 1 (CLK1), a kinase known to phosphorylate SRSF 25 family splicing factors among other proteins (18). However, in line with the 26 specific biology of PIs, Cfz also strongly induced inhibitory kappa B kinase 27 (IKBKB) activity, a kinase leading to NF-kB inhibition after PI treatment (19). 28
Taken together, these results indicate that drug-induced stress may broadly lead 29 to phosphorylation of splicing factors, though precise patterns of phosphorylation 30 may differ in a drug-specific manner. we performed Western blots to evaluate for phosphorylation-induced gel mobility 4 shift after Cfz treatment of SRSF1, SRSF3, and SRSF6. After Cfz treatment and 5 isolation of the cytoplasm, we initially saw no discernable shift of these proteins. 6
However, treatment of lysate with calf alkaline phosphatase resulted in a 7 substantial shift of SRSF proteins but not actin (Fig. S3F) . Therefore, these 8 SRSF factors exist in a highly phosphorylated state even at baseline in MM 9 plasma cells. Upregulated phosphorylation post-Cfz identified by mass 10 spectrometry may therefore represent additional phosphorylation at only selected 11 phosphosites. While these changes in phosphorylation may still result in 12 biological effects, Cfz-induced modulation does not appear to reflect a dramatic 13 shift in the overall phosphorylation status of these SRSF proteins in this system. quantified SRSF phosphosites, except one upregulated (Fig. S2F) . These results 21
suggest that other kinases also play a role in maintaining SRSF phosphorylation 22 in this system, either at baseline or via feedback mechanisms after sustained 23
CLK1 inhibition. 24 25
Proteasome inhibition induces intron retention in MM cells 26
Given our results demonstrating splicing factor phosphorylation, we next 27 investigated whether pre-mRNA splicing itself was altered after drug treatment. 28
We obtained paired-end sequencing data from polyA-enriched RNA on the same 29 samples used for phosophoproteomics, plus one additional biological replicate (n 30 = 3 total) of each of the following: MM.1S treated with 18 nM Cfz, with 10 µM 31 melphalan, and with DMSO as control; and AMO-1 treated with 15 nM Cfz and 1 with DMSO as control. We used JuncBASE (21) to process the aligned 2 sequencing data by identifying and quantifying both annotated and novel splice 3 junctions. Data for each alternative splicing event was evaluated using the 4 standard measure of "percent spliced in" or PSI (ψ) (Fig. 3A) . 5
Comparative analysis of differential PSI (ΔPSI) between 18 nM Cfz-and 6 DMSO-treated MM.1S were considered according to categories including 7 alternative exon acceptor (3' splice site selection), alt. donor (5' splice site 8 selection), alt. last exon, alt. first exon, alt. exon cassette, and intron retention 9 (IR) (Fig. 3B, Supplementary Table S3 ). The ΔPSI distribution for IR 10 demonstrated the greatest positive shift after Cfz treatment (n = 25,807 total IR 11 events measured; median = 2.54). ΔPSI medians for alternative splice site 12 selection also demonstrated a significant shift (alt. donor median = 1.64, n = 13 9,188 and alt. acceptor median = 0.81, n = 9,352). All other categories were 14
closer to a median of zero (p < 2.2E-16 for median of IR distribution, alt. donor, 15 and alt. acceptor vs. median of cassette by Mann-Whitney test, Supplementary 16 Table S3 ). Intriguingly, PIs are well known to induce a strong heat shock 17 response (12) and prior work in non-cancer cells demonstrated that heat shock 18 alone could impair splicing and induce IR without broadly affecting other 19 alternative splicing events (22, 23). In general, intron-retained transcripts may be 20 subject to nonsense-mediated decay or retained in the nucleus where they 21 remain untranslated. Our results suggest that a similar splicing impairment may 22 be present in MM cells exposed to PI. 23
We then considered the possibility that the IR phenotype results from a 24 global dysfunction of the splicing machinery during drug-induced apoptosis, 25 which is likely occurring with ~85% cell death at our high-dose Cfz treatment. Our 26 prior proteomic data indicated that SF3B1 and U2AF2, core components of the 27 splicing machinery, are some of the earliest substrates cleaved by caspases 28 during PI-induced apoptosis (9). Indeed, by Western blotting we validated that 29 SF3B1 and U2AF2 are proteolytically cleaved after Cfz treatment and this 30 cleavage can be blocked by the pan-caspase inhibitor zVAD-fmk (Fig. S3E) . 31 These caspase cleavage events, then, could be responsible for the IR 1
phenomenon. 2
However, we found a similar shift in IR distribution in AMO-1 cells treated 3 with 15 nM Cfz (n = 27,386; median = 2.2) (Fig. 3C) despite much less cytoxicity 4 (~20%) than the 18 nM Cfz treatment in MM.1S. As caspase cleavage correlates 5 with degree of cell death, it therefore appears unlikely that cytotoxicity alone is 6 responsible for IR. Notably, an even smaller shift was observed in IR for MM.1S 7 with 10 µM melphalan treatment, also at ~20% cytotoxicity (n = 24,247; median = 8 0.44; p < 2.2E-16 for IR distribution MM.1S 18 nM Cfz vs 10 µM melphalan). 9
Instead, after melphalan the greatest ΔPSI shift occurred with alt. exon cassettes 10 correlates with the lesser degree of splicing factor phosphorylation (Fig. 2) . 22
These findings illustrate a more pronounced IR phenotype after PI than DNA 23 damage, irrespective of the amount of cell death, while alternative exonic splice 24 site determination may be a dose-response behavior. 25
26
Exogenous expression of SRSF1 wildtype and RS-domain mutants do not 27 significantly alter splicing patterns 28
Having shown that proteasome inhibition can lead to both robust splicing 29 factor phosphorylation as well as widespread IR of pre-mRNA, we next 30 considered whether these processes are causally linked or whether they instead 31 occur via parallel mechanisms. To initially investigate this question, we 1 considered SRSF1 (also known as SF2 or ASF), a well-characterized member of 2 the SR family of splicing factors and a putative proto-oncogene (16, 25). All 3 members of this family contain RNA recognition motifs (RRM) and arginine-and 4 serine-rich domains (RS) (16). In general, SR proteins recognize cis-acting splice 5 enhancers on pre-mRNA and work to promote splicing by initially recruiting the 6 spliceosome to these intron-exon junctions (16). We found that SRSF1 7
demonstrates upregulated phosphorylation at sites in both the RS1 and RS2 8 domain when MM cells are treated with Cfz ( Fig. 2A, Supplementary Table S4 ). 9
The current model of SRSF1 function suggests that 1) SR-protein kinases 10 (SRPK)-mediated phosphorylation of RS domain leads to translocation into the 11 nucleus, 2) further hyperphosphorylation by CLK1 causes association with the 12 U1 spliceosome, and 3) partial dephosphorylation is required for splicing 13 catalysis (16, 26, 27). and SD signal is localized to the nucleus, suggestive of functional protein product 30 and consistent with expected biology. However, a much larger fraction of SA 31 mutant is trapped in the cytosol despite NLS tagging. Consistent with prior work 1 (30, 31), this finding suggests that phosphorylation of RS domains is a major 2 requirement for entry into the nucleus. 3
Upon JuncBASE analysis of poly-A RNA-seq data from DMSO-treated 4 WT, SD, and SA construct (n = 3 for each), we saw remarkably few global 5 differences in PSI as a function of modeled SRSF1 phosphorylation status (Fig.  6   4D) . Notably, our results in Fig. 1B suggested that phosphorylation of multiple 7 splicing factors, including other SRSF proteins, occurs simultaneously under Cfz-8 induced stress; we find that altered phosphorylation of SRSF1 alone may not 9 carry any significant effects. 10
11
SRSF1 RS-domain phosphomimetic mutant demonstrates weakened 12 interaction with the spliceosome 13
Though we cannot draw a direct link between SRSF1 phosphorylation 14 status and specific alternative splicing events, we further investigated the diverse 15 biological roles of SRSF1. In addition to modulating pre-mRNA splicing, these 16 include regulating nuclear export of spliced mRNAs and translational regulation 17 in the cytosol via interaction with the ribosome (32-34). Using the 3x-FLAG tag 18 on constructs we performed affinity purification mass spectrometry (AP-MS) with 19 label-free quantitative proteomics vs. an mCherry-NLS-[FLAG] 3 control. We 20 specifically evaluated differential binding partners of SRSF1 as a function of 21 phosphorylation status across both the nuclear and cytoplasmic compartments. 22
While clear differences were observed between the nuclear and cytosolic 23 interactome for each construct, overall biological signatures based on GO 24 analysis were surprisingly similar across WT, SD, and SA within each 25 compartment (Fig. S5B, D, F) . Notably, in the cytosol we found consistent 26 interactions between both SRSF1-WT and SRSF1-SD with several RNA-binding 27 proteins as well as components of the translational machinery. We do note one 28 stark difference between WT and the phosphomimetic mutant in the nuclear 29 fraction: the WT construct showed direct evidence of interaction with several 30 small nuclear ribonucleoprotein (snRNP) polypeptides, core components of the 31 U1-U2 spliceosome (Fig. 4E) . Unexpectedly, these nuclear interactions were not 1 enriched in the SD construct, which instead interacted with other splicing-related 2 factors such as TRA2A, TRA2B, and PABPN (Fig. 4F) . This interactome 3 mapping may help refine the current model of SRSF1 biology, which suggests 4 that hyperphosphorylation of RS domains leads to preferential integration with 5 the U1 spliceosome (35, 36) and would explain the lack of change seen in global 6 alternative splicing in the SD expressing cells. We next explored the splicing-level effects of 15 nM Cfz treatment on 11 AMO-1 cells expressing the WT, SD, and SA constructs. Notably, in this setting 12 cytotoxicity at 24 hr was <10% in 8 of 9 total replicates (Fig. S4D) . Compared to 13 DMSO-treated samples (Fig. 4C) , Cfz again elicited a response consistent with 14 that found in Fig. 3C : despite minimal cell death, we observed a clear shift in the 15 median ΔPSI toward increased global IR (n = 12,139; median = 2.45, p < 2.2E-16 16 for one-sample Wilcoxon summed rank test). These findings in the absence of 17 apoptosis underscore that caspase cleavage of splicing factors is unlikely to be a 18 primary mechanism of IR after PI. 19
The combined RNA-seq dataset of all Cfz-treated samples vs. DMSO for 20 these additional SRSF1 constructs were analyzed together ( Fig. 5A) with 21 JuncBASE (n = 24 replicates total across all AMO-1, including data in Fig. 3C , 22 4C). With this increased statistical power, we were able to identify CNNM3, which 23 encodes a divalent metal cation transporter, as showing among the strongest 24 signatures of IR across all events (FDR-corrected p = 0.032) (Fig. S4G) . 25 However, despite detecting n = 22,559 IR events by JuncBASE (Fig. 5B, left) , 26 very few individual transcripts (n = 43, including CNNM3) showed statistically 27 significant (FDR-corrected p < 0.05) IR across replicates (Fig. 5B, right) . This 28 finding suggests that Cfz-induced IR may be a stochastic process, perhaps 29
resulting from general interference with the splicing machinery without a coherent 30 selection for specific transcripts. 31
In contrast, alternative exon splice site usage (alternative exon donor (n = 1 1134) and alternative exon acceptor (n = 810)) emerged as the dominant type of 2 alternative splicing when considering only statistically significant events (Fig.  3   5B) . We investigated whether these consistently observed alternative splicing 4 events may carry some biological relevance. Interestingly, GO enrichment 5 analysis of all the genes undergoing significant alternative splicing after Cfz (n = 6 2,575 events total across all categories in Fig. 5B, right) revealed 'proteasome-7 mediated ubiquitin-dependent protein catabolic process' (p = 2.08E-16) and 8 'protein polyubiquitination' (p = 1.39E-13) as highly enriched (Fig. 5C) . Notably, 9 multiple proteasome subunits (PSMA3/5/7, PSMB4/5, PSMC1/4/5, PSMD1-4, 10 PSME2), the protein homeostasis node p97 (VCP), and ubiquitin (UBB, UBC) all 11 undergo some degree of alternative splicing with Cfz (example in Fig. 5D ). These 12 findings raise the possibility that alternative splicing may modulate the protein 13 homeostasis machinery in response to therapeutic proteasome inhibition. 14 Taken together, our results offer a model for the effects of proteasome 15 inhibition on the splicing machinery in myeloma (Fig. 5E) . Upon therapeutic 16 insult, the stress response induces phosphorylation of multiple splicing factors. 17
Though the effect of this phosphorylation on specific splicing events remains 18 unclear, these events may relate to specific alterations in exon usage based on 19 known SRSF biochemistry. Our analysis of specific exon usage suggests that 20 modification of the proteasome itself via alternative splicing may play a role in 21 adaptation or resistance to proteasome inhibitor. In parallel, we observe a broad 22 increase in the number of stochastically distributed IR events. These IR events, 23 expected to reduce the number of functional protein products, may work to 24 generally reduce proteotoxic stress and conserve cellular resources normally 25 devoted to protein synthesis, thereby playing a role in adaptation to proteasome 26 inhibition. Alternatively, the intron retention phenotype may indicate malfunction 27 of the spliceosome, an essential process whose loss reduces tumor cell fitness. 28
Interference with splicing may therefore be a previously unappreciated part of the 29 PI mechanism of action. (Fig. S6B) as well as JuncBASE analysis of RNA-seq data (Fig. 6A) , as 12 expected we identified very significant IR after 6h of 10 nM E7107 treatment in 13 MM.1S cells (ΔPSI median = 13.79, n = 30,666). There was no noted cytotoxicity 14 at this early time point (Fig. S6A) . This finding supports the previous conclusion 15 that splicing impairment, not apoptosis, induces IR. However, unlike the PI 16 response, we also observed massive global loss of cassette exon splicing under 17 E7107 (ΔPSI median = -16.6, n = 24,053, Fig. S6D) . Furthermore, the number of 18 significant (p < 0.05) IR events remained very high with E7107 (n = 7,171), unlike 19 the apparently stochastic IR events seen with PI (Fig. S6C) . Altogether, this 20 suggests that PI-induced impairment of splicing is a partial interference of normal 21 splicing operations, unlike the total abrogation of splicing seen with E7107. 22
Underscoring the potential of splicing inhibition as a therapeutic strategy in MM, 23 E7107 was extremely potent versus a panel of seven MM cell lines treated for 48 24 hr, with LC 50 's ranging from <1 nM to 30 nM (Fig. 6B) . In addition, a PI-resistant 25 AMO-1 cell line (39) showed very similar sensitivity to E7107 as the parental line 26 (Fig. 6C) . This finding suggests the potential for clinical utility of splicing inhibition 27 even in PI-refractory disease. 28
We noted that our MM cell line sensitivities appeared essentially bimodal, 29
with one group of more sensitive lines with LC 50 's of <1 nM and another slightly 30 less sensitive group of cell lines with LC 50 of 20-50 nM. In an attempt to identify 31 potential determinants of this differential drug sensitivity, we examined publicly 1 available RNA-seq data of baseline gene expression in MM cell lines 2 (www.keatslab.org). We were intrigued to find that the more sensitive lines 3 demonstrated significantly higher RNA expression of SF3B1 (Fig. 6D) . This 4 outcome hinted that more sensitive cell lines may somehow be more "addicted" 5 to SF3B1, leaving them more vulnerable to splicing inhibition, as well as 6 revealing a potential biomarker that could be used for patient stratification. 7
Unfortunately, this result was not confirmed at the protein level (Fig. 6E),  8 suggesting that SF3B1 may undergo post-transcriptional regulation. We found no 9 other candidates for markers of sensitivity or resistance to E7107 based on 10 available DNA or RNA sequencing data from this limited cohort of cell lines. 11
We further explored the hypothesis that interfering with splicing via two 12 different mechanisms may lead to synergistic MM cell death. Indeed, 13 combination studies with Cfz and E7107 showed strong synergy across the 14 dosing landscape based on ZIP synergy scoring (40) (Fig. 6F-G) . In contrast, 15 melphalan, which induced much less IR than PI (Fig. 3B-C) , showed much 16 weaker synergy in combination with E7107 ( Fig. 6H-I) . These findings support 17 the approach of using splicing inhibitors in combination with PIs in MM treatment. human disease (41). We found that E7107 was generally well-tolerated with no 27 appreciable weight loss (Fig. S7A) . At 3 mg/kg E7107 I.V., a relatively low dose 28 compared to prior studies in other malignancies (37), we still found pronounced 29
anti-MM effect after a brief 2 week treatment (Fig. 7A-C) . This suppression of 30 tumor translated into a significant survival benefit (p = 0.01, log-ranked test; n = 6 1 per arm). 2
We next turned to ex vivo evaluation versus primary patient samples. 3
Fresh bone marrow mononuclear cells from seven PI-refractory MM patients 4
were treated for 48 hr with varying doses of E7107. Based on flow cytometry 5 analysis of CD138+ plasma cells (Fig. S7B) , we found similar high sensitivity of 6 patient tumor cells to E7107 as found in cell lines, with estimated LC 50 's in the 7 low-nM range (Fig. 7D) . Notably, non-plasma cell bone marrow mononuclear 8 cells (CD138-fraction) showed remarkably little cytotoxicity at these same doses, 9 supporting a potential therapeutic index for splicing inhibitors in MM. 10 11
Functional genomics and whole exome sequencing suggests clinical 12 applications of splicing inhibition in MM 13
Analysis of CRISPR essentiality screen data in the Cancer Dependency 14
Map (www.depmap.org; Avana library public 18Q4 (42)), across over 400 cancer 15
cell lines, demonstrated that myeloma has among the strongest genetic 16 dependencies on the target of E7107, SF3B1 (Fig. S7C) . This genetic ablation 17 data further supports the ability to pharmacologically eliminate MM tumor cells 18 via splicing inhibition while sparing normal cells. We further extended this 19 analysis to other core components of the U1-U2 spliceosome found to be 20
"common essential" genes per DepMap (43). By aggregating DepMap rankings, 21
we found that MM cell lines are the most sensitive tumor cell type to genetic 22 ablation of these central snRNP protein components, necessary for association 23 with pre-mRNA and splicing catalysis (Fig. 7E) . Compared to the essential 24 subunits of the 20S proteasome (including the direct PI target PSMB5) (Fig.  25   S7D) , we surprisingly found more favorable genetic evidence for targeting the 26 spliceosome in MM than the proteasome. (Fig. S7E) , though LC 50 's (0.3 ->20 µM) were much higher than those for the 2 SF3B1 inhibitor E7107. In DepMap data, MM was again among the more 3 sensitive tumor type to RBM39 ablation (Fig. S7F) . Indisulam may therefore 4 represent another approach to targeting the spliceosome in this disease, though 5 given lower potency the potential for clinical translation is less clear. 6
We next took advantage of genomic and transcriptomic data from isolated 7 malignant plasma cells from newly-diagnosed MM patients in the Multiple 8 Myeloma Research Foundation CoMMpass study (research.themmrf.org; version 9 IA11). First evaluating gene expression data, we intriguingly found significantly 10 decreased progression-free survival among patients in the top quartile of SRSF1 11 expression versus those in the bottom quartile (p = 0.0081 by log-ranked test) 12 and a trend toward similarly decreased overall survival for patients in the top vs. 13 bottom quartile of SF3B1 expression (p = 0.087) (Fig. S7G) . These results raise 14 the possibility of poorer outcomes in patients whose disease is more dependent 15 on the spliceosome. 16
However, we note that both E7107 (37) and the recently described 17 splicing inhibitor H3B-8800 (38) have both been shown to have the greatest 18 potency versus hematopoietic malignancies carrying mutations in splicing factors 19 such as SF3B1, SRSF2, U2AF2, and ZRSR2 (45). These mutations are seen 20 frequently in myelodysplastic syndromes (MDS), acute myeloid leukemia, and 21 chronic lymphocytic leukemia, appearing in up to 50% of MDS patients (45). We 22 therefore examined exome sequencing data available in CoMMpass and found 23 that 28.0% of MM patients (268 of 956) were found to carry missense mutations 24 within at least one of 119 splicing-associated factors recently proposed to be 25 most relevant to tumorigenesis across a survey of the The Cancer Genome Atlas 26 (Fig. 7F, Supplementary Table S6 ) (46). While only a small minority of these 27 identified mutations has been functionally validated to affect splicing, the most 28 common single mutation was at the known "hotspot" SF3B1 K666T, found in 29 three patients. Variant allele frequencies for these expected heterozygous 30 mutations were 42%, 35%, and 22%, suggestive of a prominent subclonal 31 fraction of the tumor cell population. Among well-characterized genes, mutations 1 were found in SF3B1 (n = 10 patients, including K666T mutations), SRSF2 (n = 2 2), U2AF1 (n = 4), and ZRSR2 (n = 1). Unfortunately we were unable to obtain 3 rare primary patient samples containing mutations in these genes, and no 4 myeloma cell lines are known to carry hotspot mutations in these well-5 characterized splicing factors (www.keatslab.org). While our data suggest that 6 spliceosome inhibition should be considered a therapeutic option for MM patients 7 of any genotype, recent work in other malignancies (37, 38) supports the 8 potential for particular benefit in the subset of patients carrying pathogenic 9 splicing factor mutations. 10 11
DISCUSSION: 12
Our results demonstrate that PI therapy in myeloma leads to both specific 13 alterations in splice site usage and broad-scale interference with spliceosome 14 function. This observation, initially generated through unbiased stress in cancer, the mechanism that leads to coordinated, upregulated 27 phosphorylation across multiple splicing factors, whether via kinase activation or 28 phosphatase inhibition, will be an important topic for future investigation. 29
We also found a correlation between PI-induced stress and both SR factor 30 phosphorylation and the degree of alternative exon selection. This finding 31 appears consistent with prior studies (16) suggesting that SR factors play a role 1 in exon selection and their activity can be modulated by phosphorylation. Why 2 these effects specifically lead to alternative splicing of protein homeostasis genes 3 remains to be investigated. In contrast, we found IR to be largely independent of 4 the degree of PI-induced stress. This result suggests that the IR phenotype is 5 mediated by a different mechanism and uncoupled from SR factor 6 phosphorylation. 
systems. 20
This PI-induced interference with normal splicing even at minimal 21 cytotoxicity, much greater than that found with melphalan, may relate to the 22 activation of the heat shock response. We found prominent heat shock 23 chaperone induction even under a non-cytotoxic dose of the PI bortezomib in 24 MM.1S cells (10). As previously shown in non-cancer cells, heat shock alone, 25 without cell death, can lead to significant intron retention (23). One hypothesis is 26 that this broad-scale inhibition of splicing acts in a similar fashion to translational 27 inhibition after drug-induced stress: a way to conserve cellular resources and 28 focus on only producing genes required for survival and the stress response. 29
However, as described in our model of Fig. 5E , and evidenced by our mRNA-seq 30 data after E7107 treatment (Fig. 6A) , another possible result of widespread 31 intron retention and downstream loss of normal protein production is significant 1 decrease in cellular fitness and ultimately, cell death. There may be a 2 quantitative threshold effect between these two outcomes that remains to be 3
elucidated. 4
Here, we propose that the loss-of-fitness modality of drug-induced IR 5 constitutes a previously unexplored mechanism of action of PIs. We further 6 performed a preclinical evaluation of splicing inhibition in myeloma using E7107, 7 finding potent anti-myeloma effects in vitro, in vivo, and ex vivo versus primary 8 patient samples. From a therapeutic perspective, one of the major questions is 9 the potential toxicity of targeting such an essential process as the catalytic 10 spliceosome. However, our analysis of genetic dependency data and our ex vivo 11 data with E7107 clearly demonstrates the potential to target core spliceosome 12 subunits in MM while largely sparing normal cells. In fact, based on this analysis 13 the spliceosome appears to be an even more promising target than the clinically-14 validated approach of targeting essential subunits of the proteasome. 
Cell culture 28
All cell lines were grown in suspension at 37°C, 5% CO 2 in complete media: 29 RPMI 1640 medium (Gibco, 22400105, UCSF CCFAE002), supplemented with 30
10% FBS (Atlanta Biologicals, S11150) for proteomics experiments and 31
Benchmark FBS (Gemini Bio-products, 100-106) for drug viability experiments 1 and 1% penicillin-streptomycin (UCSF, CCFGK003). INA6 cell media was 2 supplemented with 90 ng/mL recombinant human IL-6 (ProSpec Bio, CYT-213). 3 4
Drug cytotoxicity assay 5
For dose-response cell toxicity assays, 1E+3 myeloma cells were seeded per 6 well in 384 well plates (Corning) using the Multidrop Combi (Thermo Fisher) and 7 incubated for 24 hr. In monotherapy cytotoxicity assays, cells were treated with 8 drug or DMSO and incubated for 48 hr, while cells were further incubated with 9 E7107 (H3) for an additional 24 hr in E7107 dual therapy combination assays. 10
Carfilzomib (SelleckChem, S2853-50mg), melphalan (Sigma, S2853-50mg), and 11 E7107 (H3 Biomedicine, CAS:630100-90-2), and KH-CB19 (sc-362756) were 12 solubilized in DMSO at 10 mM. Table S1 ). RNA and DNA quantified at all steps by 30 Nanodrop (Thermo Scientific) and cDNA library size and quality were evaluated 31 on a Bioanalyzer 2100 (Agilent) with High Sensitivity DNA Kit (Agilent, 5067-1 4626), before being submitted for next generation sequencing on a HiSeq4000 2 (Illumina) at the UCSF Center for Advanced Technologies core facility. 3 4
JuncBASE alternative splicing analysis 5
Alternative splicing events were identified and quantified with JuncBASE v1.2-6 beta using default parameters (21) . Intron-exon junction database was created 7 from hg19 annotations. T-test was used to compare number of inclusion and 8 exclusion reads and p-values were adjusted with Benjamini-Hochberg correction. 9
For ΔPSI histograms in Fig. 3B-C, 4C-D, and 5A , JuncBASE output included a 10 subset of alternative splice events with median PSI = 0.00 in both conditions or 11 median PSI = 100.00 in both conditions, resulting in ΔPSI = 0.00. These events 12
were manually removed for downstream analyses. Histograms and splicing 13 statistics were determined with statistical computing program R (v3.5.1) and a 14 summary is listed in Supplementary Table S3 . was assessed through weekly bioluminescent imaging in the UCSF preclinical 5 therapeutic core on a Xenogen In Vivo Imaging System (IVIS), beginning 13 days 6 after implantation, which is the same day as treatment initiation. Tumor implanted 7 humanized mice were randomized and sorted into control arm and treatment 8 arm, 6 mice/arm. Mice were treated for two weeks (five days on, two days off) 9 with vehicle or 3 mg/kg E7107, formulated in vehicle (10% Ethanol, 5% Tween-10 80, QS with Saline) and administered by continuous subcutaneous infusion. Mice 11 were kept and observed until survival endpoint; final timepoint was 54 days after 12 MM.1S transplant. Acquired luciferase intensities were quantified with Living 13
Image Software (PerkinElmer) in units of radiance (photons/s/cm 2 /sr). Kaplan-14 meier survival curves along with log-ranked test to determine significance were 15 calculated in GraphPad Prism 6 software. 
Statistical Analyses 6
All data are presented as mean +/-standard deviation, unless otherwise stated. 7
Statistical significance in proteomics comparisons was determined by Student's t-8 test: One-sample t-test with null hypothesis that log 2 -transform of the normalized 9 SILAC ratio = 0, or a two-sample T-test with null hypothesis that the difference in 10 log 2 -transform of the intensities is equal to. A p < 0.05 is considered statistically 11 significant. For all Kaplan-Meier survival analysis, log-ranked test was used to 12 determine statistical significance. 13
14
Data Availability 15
The 
